Phase III Trial Progress
Announced the last patient visit for the Phase III trial RETHINK-ALZ, with top-line results expected by the end of the year.
Cash Position and Financial Stability
Ended Q3 with $149 million in cash, expected to fund operations through the conclusion of ongoing Phase III trials and into 2026.
Reduced R&D Expenses
R&D expenses for Q3 were $17.7 million, down from $23.6 million in the same period last year as more patients transition from Phase III to lower-cost open-label studies.
Biomarker Innovation
Discussed the potential of plasma biomarker tests with high correlation to Alzheimer's diagnosis, which could transform treatment by primary care physicians.